ProQR Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ProQR TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 3.3% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 33.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -108.1% betragen.

Wichtige Informationen

-3.3%

Wachstumsrate der Gewinne

4.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	33.3%
Zukünftige Eigenkapitalrendite	-108.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PRQR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	12	-47	-52	-66	3
12/31/2025	16	-27	-18	-30	5
12/31/2024	22	-27	N/A	-29	3
9/30/2024	18	-24	-26	-32	N/A
6/30/2024	16	-22	-28	-34	N/A
3/31/2024	11	-27	-32	-38	N/A
12/31/2023	7	-28	28	22	N/A
9/30/2023	5	-36	8	9	N/A
6/30/2023	4	-54	1	1	N/A
3/31/2023	4	-59	-4	-3	N/A
12/31/2022	4	-64	-69	-69	N/A
9/30/2022	4	-69	-48	-47	N/A
6/30/2022	4	-61	-40	-40	N/A
3/31/2022	3	-63	-35	-35	N/A
12/31/2021	2	-61	-26	-26	N/A
9/30/2021	2	-57	-42	-42	N/A
6/30/2021	2	-55	-44	-43	N/A
3/31/2021	1	-43	-45	-44	N/A
12/31/2020	1	-47	-48	-47	N/A
9/30/2020	1	-52	-48	-47	N/A
6/30/2020	1	-51	-47	-46	N/A
3/31/2020	2	-58	-47	-47	N/A
12/31/2019	2	-56	-45	-44	N/A
9/30/2019	3	-51	-41	-41	N/A
6/30/2019	5	-45	-37	-37	N/A
3/31/2019	6	-40	-32	-31	N/A
12/31/2018	6	-37	-29	-28	N/A
9/30/2018	4	-35	-28	-28	N/A
6/30/2018	2	-40	N/A	-31	N/A
3/31/2018	1	-44	N/A	-36	N/A
12/31/2017	1	-44	N/A	-35	N/A
9/30/2017	1	-41	N/A	-34	N/A
6/30/2017	1	-41	N/A	-37	N/A
3/31/2017	1	-39	N/A	-35	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	3	-36	N/A	-34	N/A
6/30/2016	3	-33	N/A	-29	N/A
3/31/2016	3	-31	N/A	-27	N/A
12/31/2015	3	-21	N/A	-24	N/A
9/30/2015	3	-17	N/A	-22	N/A
6/30/2015	1	-14	N/A	-20	N/A
3/31/2015	1	-10	N/A	-18	N/A
12/31/2014	0	-12	N/A	-14	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-9	N/A	-7	N/A
3/31/2014	0	-5	N/A	-4	N/A
12/31/2013	0	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRQR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PRQR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PRQR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PRQRDie Einnahmen des Unternehmens (33.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: PRQRDie Einnahmen des Unternehmens (33.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PRQR wird voraussichtlich in 3 Jahren unrentabel sein.

ProQR Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 40% to US$5.73

Consensus revenue estimates increase by 35%

Consensus revenue estimates increase by 28%

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 15%

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 40% to US$5.73

ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million.

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. has filed a Follow-on Equity Offering.

ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus revenue estimates increase by 35%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Consensus revenue estimates increase by 28%

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates increase by 64%, EPS downgraded

Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €170 million.

New minor risk - Share price stability

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates decrease by 25%

Consensus EPS estimates upgraded to €0.24 loss, revenue downgraded

Price target decreased by 9.2% to US$3.82

ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Price target increased to US$3.25

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ProQR Therapeutics N.V. Appoints Jurriaan Dekkers as Chief Financial Officer

Consensus forecasts updated

ProQR Therapeutics N.V. to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Consensus revenue estimates increase by 25%

ProQR says EU regulator seeks additional trial for lead candidate

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProQR Therapeutics N.V. Appoints Rene Beukema as Member of Management Board

ProQR Therapeutics N.V., Annual General Meeting, Jun 30, 2022

Consensus estimates of losses per share improve by 11%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$3.29

Price target decreased to US$3.64

ProQR Therapeutics N.V. Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for Proqr's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$13.50

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ProQR Therapeutics N.V. Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

ProQR Therapeutics N.V. Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421A for USH2A Mediated Retinitis Pigmentosa

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Consensus forecasts updated

Phoenicis Therapeutics Inc. acquired Wings Therapeutics, Inc from ProQR Therapeutics N.V. (NasdaqGM:PRQR) and others.

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year